Best Genomics Companies in Colorado, United States
The 39 best Genomics companies in Colorado, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Inscripta.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Colorado
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Inscripta Developer of gene editing technology for research | $499M | 44 mo ago | 176 | Andrew Garst Co-Founder | WordPressApple iCloud MailMicrosoft 365+24 | Top 10M | 654 patents CRISPR-based genome editing platforms and engineered microbes for synthetic isoprenoid production | — |
| 2 | Evolutionary Genomics Developer of genes for pest and disease resistance in plants | $176M | 51 mo ago | 2 | Steve Warnecke CEO | — | — | 75 patents Genetically engineered crops for disease resistance, drought/salt tolerance, and hybrid seed production | — |
| 3 | ArcherDX Developer of molecular cancer diagnostic products | $153M | 80 mo ago | 429 | John Iafrate Co-Founder | — | — | 107 patents Patents concentrated in chemistry & materials | — |
| 4 | Foresight Diagnostics Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 25 mo ago | 35 | Ash Alizadeh Co-Founder | WordPressApple iCloud MailMySQL+21 | Top 5M | — | — |
| 5 | OPX Biotechnologies Renewable converstion to biofuel | $60M | 182 mo ago | 61 | — | — | — | 120 patents Microbial biosynthesis of platform chemicals like 3‑hydroxypropionic acid and 1,4‑butanediol | — |
| 6 | Watchmaker Genomics Developer of gene-editing technology | $48M | 51 mo ago | 121 | Brian Kudlow Co-Founder | WordPressApple iCloud MailGoogle Workspace+26 | Top 5M | 36 patents Advanced nucleic‑acid library prep and engineered polymerases for next‑gen sequencing | 2 launchs |
| 7 | MiRagen Developer of microRNA-based therapeutic solutions for treating multiple diseases | $44M | 70 mo ago | 92 | Sanjoy Mahanty Co-Founder | — | — | — | — |
| 8 | CellPoint Developer of intra-nuclear molecular imaging and therapeutics for multiple diseases | $30M | 62 mo ago | 185 | — | — | — | 4 patents Targeted peptide-drug conjugates for tissue-specific disease imaging | — |
| 9 | Think Bioscience Provider of synthetic biology platform to develop small-molecule therapeutics 22Funding top 30%Talent top 38%Moat top 39%Global bottom 39% All 6 signals ▾Fundingtop 30% Talenttop 38% Moattop 39% Globalbottom 39% Techbottom 30% Marketbottom 28% Funding: Raised $26.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 22/100 | $26M | 7 mo ago | 21 21 → 31 (+48%) | Jerome Fox Co-Founder & CEO | WordPressMySQLPHP+11 | Top 50M | — | — |
| 10 | Arpeggio Provider of drug discovery platform for the treatment of cancer 24Funding top 27%Moat top 31%Talent top 38%Global bottom 37% All 6 signals ▾Fundingtop 27% Moattop 31% Talenttop 38% Globalbottom 37% Marketbottom 25% Newsbottom 22% Funding: Raised $25.4M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $25M | 9 mo ago | 8 | Laura Norris Co-Founder | — | — | — | — |
| 11 | KromaTiD Provider of molecular and genetic tests for detection of disease-causing mutations | $7M | 14 mo ago | 31 | — | HubSpot CMS HubBugHerdAmazon Web Services+15 | Top 50M | 22 patents Chromosome stability and genotoxicity analysis using advanced spectral karyotyping methods | 1 internship |
| 12 | Crestone Pharma Manufacturer of small molecule drugs for infectious diseases | $7M | 18 mo ago | 8 | — | WordPressMySQLPHP+17 | Top 50M | — | — |
| 13 | FluoroFinder Design and search tool to find the best flow cytometry products for the panel | $5M | 15 mo ago | 12 | John Allen CEO | WordPressMySQLPHP+25 | Top 1M | — | — |
| 14 | Orbit Genomics Developer of cancer diagnostics and companion diagnostics for drugs in development | $4M | 17 mo ago | 6 | Dede Willis Co-Founder & CEO | — | — | 15 patents Microsatellite genotyping and sample classification tools for genomic analysis | — |
| 15 | Topogen Provider of products and services for researchers | $3M | 73 mo ago | 7 | — | WordPressMySQLPHP+36 | Top 10M | 3 patents Non‑invasive urinary biomarker assays for bladder cancer detection | — |
| 16 | Z biotech Glycomics solutions provider advancing research with innovative glycan microarray technology | $2M | 13 mo ago | 6 | — | — | — | 109 patents Closed-system cryopreservation devices with integrated tracking for biological samples | — |
| 17 | BioRealm Bioinformatics, statistics, and IT solutions for research challenges | $2M | 101 mo ago | 6 | Carolyn Ervin Co-Founder | — | — | 2 patents Machine‑learning based biosignature identification for substance‑use disorder diagnostics | — |
| 18 | Sachi Bioworks Developer of an integrative bioinformatics platform for drug discovery using AI | $2M | 17 mo ago | 5 | Anushree Chatterjee Co-Founder & CEO | — | — | — | — |
| 19 | Eleven P15 Developer of genetically-targeted therapeutic for pulmonary fibrosis | $2M | 82 mo ago | — | David Schwartz Founder | — | — | 5 patents Early detection of pulmonary fibrosis via circulating biomarker assays | — |
| 20 | Source MDx Molecular diagnostic solutions for early detection of cancer | $2M | 198 mo ago | — | — | — | — | 19 patents Gene expression biomarker panels for diagnosing and monitoring autoimmune diseases | — |
| 21 | The BioCollective Microbiome research products and services for advancing scientific discovery | $1M | 78 mo ago | 6 | Martha Carlin Co-Founder & CEO | — | — | 5 patents Probiotic therapeutic formulations and microbiome delivery devices for health applications. | — |
| 22 | Greffex Developer of an adenoviral vector technology platform for vaccine delivery | $155K | 66 mo ago | 14 | John Price President & Chief Executive Officer | — | — | 52 patents Patents concentrated in chemistry & materials | — |
Top 12 Genomics companies in Colorado
#1
Series A · Boulder, Colorado · founded 2019 · 21 employees$26Mraised▾
Provider of synthetic biology platform to develop small-molecule therapeutics. The company's platform combines applied microbiology, enzymology, and data science to develop medicines against difficult-to-drug proteins.
- Jan 2026Series A$55M
- May 2024Seed$6M
- Aug 2022Seed$17M
- Dec 2020Grant (prize money)$255.9K
#2
Series B · Boulder, Colorado · founded 2017 · 8 employees$25.4Mraised▾
Provider of drug discovery platform for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening technology to identify therapeutic targets and biomarkers to treat cancer. The company is developing drug candidates for Sarcomas, Lung Adenocarcinoma, and autoimmune diseases.
- Nov 2025Series B$20M
- Mar 2025Series A$4M
- Aug 2022Series A$20.2M
- Jan 2020Seed$3.2M
#3
Series C · Fort Collins, Colorado · founded 2007 · 31 employees$7.4Mraised▾
Provider of molecular and genetic tests for detection of disease-causing mutations, including inversions and translocations, in a single test. Based on its patented Directional Genomic Hybridization (dGH), KromaTiD’s assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies. KromaTiD’s research products and services help in a deeper understanding of genetic diseases, including cancers and developmental disorders.
- Jul 2025Series C$8M
- Jan 2024Series A$2.1M
- Apr 2021Series A$2M
- Jan 2021Grant (prize money)$1.6M
#4
Series A · Westminster, Colorado · founded 2008 · 12 employees$4.7Mraised▾
Design and search tool to find the best flow cytometry products for the panel. It aims at simplifying the complexity of managing the life-cycle of building and iterating a flow cytometry panel. It claims FluoroFinder’s flow cytometry panel builder tool simplifies the panel design process, reduces errors, and saves time.
- May 2025Grant (prize money)$2.5M
- Sep 2022Grant (prize money)$1.6M
- Nov 2021Grant (prize money)$250K
- Jan 2019Series A$100K
#5
Funding Raised · Aurora, Colorado · founded 2013 · 6 employees$2.3Mraised▾
Glycomics solutions provider advancing research with innovative glycan microarray technology. This biotech company specializes in glycan microarray products and services, enabling researchers to gain insights into glycobiology for human health and disease understanding. Leveraging expertise in glycobiology, glycoengineering, and surface chemistry, they offer a range of products including glycan & lectin arrays, glycopeptide microarrays, assay buffers, and glycan-binding reagents. Services encompass glycan microarray analysis, glycosylation analysis, and custom glycan & glycopeptide synthesis. The company's technology supports applications in cancer research, influenza research, and drug discovery. They provide personalized guidance, study design assistance, sample handling recommendations, and data interpretation support. The company is dedicated to innovation, rigor, and quality, providing outstanding solutions and support for biotech, pharmaceutical companies, and leading research institutes. They offer a one-stop glycomics shop, helping to realize the promise of glycobiology research and reveal novel discoveries.
- Aug 2025Grant (prize money)$306.8K
- Aug 2025Grant (prize money)$314K
- Apr 2025Grant (prize money)$1.6M
#6
Funding Raised · Boulder, Colorado · founded 2015 · 8 employees$6.6Mraised▾
Manufacturer of small molecule drugs for infectious diseases. The lead candidate CRS3123 is a narrow-spectrum protein synthesis inhibitor for Clostridium difficile infections. The other lead candidates Oral Gram-positive and NTM/TB include a DNA polymerase inhibitor for Gram-Positive bacteria (MRSA, Streptococcus, etc.), and Tuberculosis.
- Feb 2025Grant (prize money)$288.1K
- Aug 2023Grant (prize money)$295.8K
- May 2020Grant (prize money)$250K
- Apr 2020Grant (prize money)$143.9K
#7
Acquired · Aurora, Colorado · founded 2020 · 35 employees$104.2Mraised▾
Developer of minimally-invasive liquid biopsy test for the detection of cancer. The company uses PhasED-Seq technology to develop liquid biopsy testing platform enabling detection of ctDNA levels in patients with solid tumors and hematologic malignancies.
- Jul 2024Series B$33M
- Apr 2023Series B$58.8M
- Jun 2021Series A$12.5M
#8
Seed · Boulder, Colorado · founded 2016 · 6 employees$4Mraised▾
Developer of cancer diagnostics and companion diagnostics for drugs in development. The company has developed technologies to accurately measure microsatellite variations and associate those variations with diseases, creating new diagnostic tools to evaluate the risk of certain cancers and for actionable clinical decision support. The company is currently developing a liquid biopsy test for the early detection of lung cancer and is also in the process of developing companion diagnostics.
- Apr 2025Grant (prize money)$2M
- Sep 2024Grant (prize money)$999.6K
- Jul 2024Seed$780K
- May 2021Grant (prize money)$250K
#9
Series E · Denver, Colorado · founded 2015 · 176 employees$499.5Mraised▾
Developer of gene editing technology for research. The product portfolio of the company includes developing a family of CRISPR enzymes (called MADzymes), bespoke nucleases for researchers and commercial partners, and a full suite of gene editing tools (software, instruments, and reagents) to increase the speed and efficiency of precision gene editing.
- Dec 2022Series E$27.8M
- Nov 2021Series E$1.9M
- Mar 2021Series E$150M
- Nov 2020Series D$58M
#10
Funding Raised · Boulder, Colorado · founded 2020 · 5 employees$2Mraised▾
Sachi Bioworks develops integrative bioinformatics platform for drug discovery using AI. The company's proprietary technology includes Facile Accelerated Specific Tool/Therapeutic (FAST) platform that has its application in systems biology, synthetic biology, chemistry, nanotechnology, and cell culture. This technology uses machine learning to analyze the target molecule. The FAST platform is used for the synthesis, purification, and delivery of novel hybrid molecules called FASTmers.
- Mar 2025Grant (prize money)$2M
#11
Public · Castle Rock, Colorado · founded 1990 · 2 employees$176Mraised▾
Developer of genes for pest and disease resistance in plants. The company identifies and validates native genes to provide resistance to disease and pests. It has identified and validated a gene in tomatoes responsible for increased sweetness. Candidate genes in cotton are in development for pest resistance and fiber length.
- May 2022Post IPO$1M
- May 2019Post IPO$490K
- Mar 2016Post IPO$2.9M
- Mar 2014Post IPO$2M
#12
Acquired · Boulder, Colorado · founded 2013 · 429 employees$152.6Mraised▾
Developer of molecular cancer diagnostic products. The company uses patented technology Anchored Multiplex PCR (AMP) for the development of in-vitro diagnostics (IVDs) and Personalized Cancer Monitoring (PCM) products for solid tumor biomarker identification. The company's product pipeline includes ArcherMET, NTRK CDx, and Fusion Plex.
- Dec 2019Series C$55M
- May 2019Series B$60M
- Mar 2018Series A$37.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Colorado is moving
A read on the academic research around Bioinformatics in Colorado — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 161 papers.
- University of Colorado Anschutz Medical Campus51
- Colorado State University42
- University of Colorado Denver38
- University of Colorado Boulder32
- Children\'s Hospital Colorado6
- Gene1→3
- Genome1→6
- Gene1→4
- Computational biology6
- MEDLINE4
- Disease3
- Cancer2
- Immunology2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.